Episode Details

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Progress toward Poliomyelitis eradication (CDC)
• Polio by the numbers (JID)
• Influenza & COVID-19 vaccination coverage among health care personnel (CDC)
• Phase 1/2a Safety & Immunogenicity of an adenovirus RSV Vaccine (JID)
• Receipt of first & second doses of JYNNEOS vaccine  (CDC)
• Distinguishing SARS-CoV-2 persistence and reinfection (CID)
• Remdesivir fact sheet for providers (Veklury)
• Bebtelovimab fact sheet for providers (FDA)
• Novavax triggers potent neutralization of Omicron sub-lineages (bioRxiV)
• Association between physical activity & vaccination protective effect (BMJ)
• PAXLOVID patient eligibility screening checklist (FDA)
• COVID-19 outcomes in 

  Listen Now